Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

Abstract

Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

1 - 144 . (canceled) 
     
     
         145 . A method for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue, comprising administering locally to pulmonary tissue of said subject an effective amount of said agent. 
     
     
         146 . A method for administering an. agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue, comprising selecting an agent that has an in vivo serum half-life of about 1 second to about 12 hours and binds a target in pulmonary tissue, and administering locally to pulmonary tissue of said subject an effective amount of said agent. 
     
     
         147 . The method of  claim 145 , wherein said agent has an in vivo serum half-life of about 1 second to about 12 hours. 
     
     
         148 . The method of  claim 145 , wherein said agent does not substantially enter the systemic circulation. 
     
     
         149 . The method of  claim 145 , wherein said agent is an antigen-binding fragment of an antibody. 
     
     
         150 . The method of  claim 149 , wherein said agent is an Fv fragment. 
     
     
         151 . The method of  claim 149 , wherein said agent is a dAb monomer. 
     
     
         152 . The method of  claim 145 , wherein a low dose effective amount is administered.